

DEC - 2 1995



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs (HFY-20)
Food and Drug Administration
5600 Fishers Lane, Room 11-44
Rockville, MD 20857

#16

Dear Mr. Wilson:

The attached application for patent term extension of U.S. Patent No. 4,338,325, which issued July 6, 1982, was filed on November 16, 1995, under 35 U.S.C. § 156.

The assistance of your Office is requested in confirming that the product identified in the application has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

Gerald A. Dost
Senior Legal Advisor
Special Program Law Office
Office of the Deputy Assistant Commissioner
for Patent Policy and Projects

(703) 305-9285

cc: David J. Levy, Ph.D.
Patent Counsel, Glaxo Wellcome Inc.
Five Moore Drive
Research Triangle Park, NC 27709

kt

PCW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

US Patent No. 4,338,325
Issue date 7/6/82
Serial No. 200,690
Filing Date 10/27/80

Commissioner of Patents and Trademarks
Washington, D. C. 20231

NOTICE OF CHANGE OF CORRESPONDENCE ADDRESS

Sir:

Attached is a copy of an Article of Amendment filed with the North Carolina Department of the Secretary of State indicating the name change of Burroughs Wellcome Co. to Glaxo Wellcome Inc.

Please direct all future correspondence relating to the US Patent identified above to Glaxo Wellcome Inc., which is the successor in interest of Burroughs Wellcome Co. Please use the following address:

Glaxo Wellcome Inc.
Patent Counsel
Intellectual Property Dept.
Five Moore Drive
Research Triangle Park, NC 27709

Please direct all phone calls to David J. Levy at (919) 483-2723.

Respectfully Submitted,

A handwritten signature in black ink, appearing to read "D J Levy", written over a horizontal line.

David J. Levy, Patent Counsel
Asst. Secretary of Glaxo Wellcome Inc.
Attorney for Patentee
Registration No. 27,655
Phone: (919) 483-2723

Glaxo Wellcome Inc.
Patent Counsel
Intellectual Property Dept.
Five Moore Drive
Research Triangle Park, NC 27709

STATE OF NORTH CAROLINA



Department of The
Secretary of State

To all whom these presents shall come, Greetings:

I, Rufus L. Edmisten, Secretary of State of the State of North Carolina, do hereby certify the following and hereto attached to be a true copy of


ARTICLES OF AMENDMENT

OF

BURROUGHS WELLCOME CO.
name changed to:
GLAXO WELLCOME INC.

the original of which is now on file and a matter of record in this office.

IN WITNESS WHEREOF, I have hereunto set my hand and affixed my official seal at the City of Raleigh, this 2nd day of November, 1995.



Rufus L. Edmisten

Secretary of State